Fasn is associated with cancer metabolism and was downregulated dramatically in SAHA/JQ1-treated cells, whereas Cpt1a and Cpt1b and the muscle differentiation factor Mef2c were elevated (Fig. 6a). Here, MEF2C is linked to cancer.